latest news releases from the newsroom
AQUAGOLD INTERNATIONAL Announces the Completion of Phase One Product Development and Readiness for Export
NEW YORK, May 19, 2009 (GLOBE NEWSWIRE) -- AQUAGOLD INTERNATIONAL (Pink Sheets:AQUI), a global distributor of premier Canadian spring water products, announces the successful completion of Phase One of its operating plan. As a result of production issues last year, AQUAGOLD embarked upon a plan to strengthen professional management. It has built a strong team to deliver on its commitment to the markets, including the need to redesign its packaging and labels, as well as to successfully implement a high quality, reliable bottling operation to deliver product for export to China.
Ethertronics Awarded 'Red Herring 100 North America'
SAN DIEGO, May 19, 2009 (GLOBE NEWSWIRE) -- Ethertronics, a leading provider of standard and customized embedded antenna solutions for wireless devices today announced that it has been selected as a winner of the Red Herring 100 North America Award. The Red Herring editorial team deploys a detailed process to whittle down a pool of 1,000 eligible, promising companies to the 200 Finalists and in a last round decided for the top 100 winners of this important North American award. Evaluations are made on both quantitative and qualitative criteria, such as financial performance, innovation, management, global strategy, and ecosystem integration. The Winners, elite executives and venture capital leaders from North America, celebrated the Top 100 Privately Held Companies in San Diego last week.
Enobia Pharma Inc.
Enobia Pharma's ENB-0040 Receives FDA Fast Track Designation
MONTREAL, May 19, 2009 (GLOBE NEWSWIRE) -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track status to ENB-0040 for the treatment of hypophosphatasia (HPP). ENB-0040 is Enobia's enzyme replacement therapy (ERT) for HPP, a rare, potentially life-threatening genetic bone disease for which there is no currently approved therapy.